2.79  -0.005 (-0.18%)		02-13 16:00
Open: 2.81 High: 2.82 Volume: 12,420,279		Pre. Close: 2.79 Low: 2.73 Market Cap: 1,687(M)

Short term
Mid term
Targets	6-month :	3.7	1-year :	4.04
Resists	First :	3.16	Second :	3.46
Pivot price	2.89
Supports	First :	2.7	Second :	2.24
MAs	MA(5) :	2.81	MA(20) :	2.9
	MA(100) :	3.74	MA(250) :	3.81
MACD	MACD :	-0.2	Signal :	-0.2
%K %D	K(14,3) :	17.8	D(3) :	18.3
RSI	RSI(14): 32.7
52-week	High :	5.34	Low :	1.63

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ GERN ] has closed above bottom band by 15.9%. Bollinger Bands are 48.2% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 9 bars. This is a sign that the market may be about to initiate a new trend.

If tomorrow:	Open lower	Open higher
High:	2.83 - 2.84	2.84 - 2.86
Low:	2.68 - 2.7	2.7 - 2.72
Close:	2.76 - 2.79	2.79 - 2.82

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in hematologic myeloid malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.

Thu, 13 Feb 2025
Geron (NASDAQ:GERN) Shares Down 4.6% - Should You Sell? - MarketBeat

Wed, 12 Feb 2025
abrdn plc Raises Stake in Geron Co. (NASDAQ:GERN) - MarketBeat

Wed, 12 Feb 2025
Is Geron Corp. (GERN) the Best Nasdaq Stock Under $5 to Buy? - Yahoo Finance

Wed, 12 Feb 2025
Geron (NASDAQ:GERN) Stock Price Down 4.6% - What's Next? - MarketBeat

Mon, 03 Feb 2025
Geron to Announce Fourth Quarter and Full-Year 2024 Financial Results on February 26, 2025 - Business Wire

Mon, 03 Feb 2025
Q4 Earnings Preview: Geron Sets Critical Financial Results Date - Key Details Inside - StockTitan

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Underperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Underperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Neutral

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares Out	0 (M)
Shares Float	605 (M)
Held by Insiders	5.5759e+008 (%)
Held by Institutions	0 (%)
Shares Short	64,520 (K)
Shares Short P.Month	0 (K)

EPS	-2.0745e+008
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	0
Profit Margin	0 %
Operating Margin	-99.9 %
Return on Assets (ttm)	-30.3 %
Return on Equity (ttm)	-69.1 %
Qtrly Rev. Growth	17 %
Gross Profit (p.s.)	271.37
Sales Per Share	5.78039e+007
EBITDA (p.s.)	-1.62549e+008
Qtrly Earnings Growth	-0.4 %
Operating Cash Flow	0 (M)
Levered Free Cash Flow	-216 (M)

PE Ratio	-0.01
PEG Ratio	0
Price to Book value	0
Price to Sales	0
Price to Cash Flow	2.9

Dividend	0
Forward Dividend	7.371e+007
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.